A Study of Isoprinosine in Patients With Severe AIDS

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the effect of Isoprinosine in patients diagnosed as having AIDS relative to:

Laboratory (immunologic defects):

• Comparison of total helper and suppressor T-cell numbers among the groups.

• Comparison of changes in natural killer cell activity.

• Comparison of other laboratory findings among the groups.

Clinical changes:

• Comparison of the frequency of opportunistic infections among the groups.

• Comparison of the frequency of the development of AIDS-related malignancies.

• Comparison of other clinical manifestations relative to severity and time of onset.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Newport Pharmaceuticals International
• Treatments: Inosine Pranobex

Criteria

Exclusion Criteria

Co-existing Condition:

Patients with a history of gout, urolithiasis, nephrolithiasis, renal dysfunction, and severe gastric ulcer are excluded.

Concurrent Medication:

Excluded:

• Steroids.

• Cytotoxic immunosuppressive agents.

• Radiotherapy.

The following are excluded:

• Critically ill patients.

• Patients receiving steroids, cytotoxic immunosuppressive agents, radiotherapy.

• Patients who have received any other immunotherapy.

• Patients with a history of gout, urolithiasis, nephrolithiasis, renal dysfunction, and severe gastric ulcer.

Prior Medication:

Excluded:

• Any other immunotherapy.

Patients with severe AIDS and specified laboratory immunologic defects.